2022
DOI: 10.1016/j.semarthrit.2022.151998
|View full text |Cite
|
Sign up to set email alerts
|

Myositis-specific autoantibodies in clinical practice: Improving the performance of the immunodot

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 32 publications
0
4
0
Order By: Relevance
“…The immunological panel for SLE-associated biomarkers included: (i) the complement fractions C3, C4 (Cobas 500 ® , Roche Diagnostics GmBH, Germany) and 50 % concentration haemolytic (CH50; SpaPlus ® , The Binding Site, Birmingham, UK); (ii) IgG anti-double stranded (ds)DNA and anti-chromatin Abs (Bioplex ® , Biorad, Hercules, CA); (iii) IgG anti-extractable nuclear (ENA) Abs against sicca syndrome (SS)A 52 kDa, SSA 60 kDa, SSB, Smith (Sm), Sm-ribonucleoprotein (RNP), RNP A, and RNP 68 kDa antigens (Bioplex ® ); (iv) IgG anti-ribosomal Abs (Bioplex ® ); (v) IgG anti-C1q Abs (Quanta-lite ® , Werfen, Barcellona, Spain); and (vi) the spot urinary sCD163 (ELLA ® , Bio-techne, Minneapolis, MN) that was evaluated together with proteinuria and creatinuria (Cobas 500 ® ) in order to express sCD163 as a ratio to creatinuria, proteinuria, or not as well as the ratio of urine protein excretion to creatinine or PCR [ [22] , [23] , [24] , [25] , [26] ]. Cut-offs were fixed as recommended by the providers (C3 low <0.72 g/L; C4 low <0.11 g/L, CH50 low <31 %; anti-dsDNA Abs ≥10 international units [IU]/mL, anti-ENA/-Ribosomal/-Chromatin Abs ≥1.0 arbitrary units [AU]mL, and anti-C1q Abs ≥20 AU/mL) with the exception of the normalized urinary sCD163/creatinuria ratio as no consensus existed.…”
Section: Methodsmentioning
confidence: 99%
“…The immunological panel for SLE-associated biomarkers included: (i) the complement fractions C3, C4 (Cobas 500 ® , Roche Diagnostics GmBH, Germany) and 50 % concentration haemolytic (CH50; SpaPlus ® , The Binding Site, Birmingham, UK); (ii) IgG anti-double stranded (ds)DNA and anti-chromatin Abs (Bioplex ® , Biorad, Hercules, CA); (iii) IgG anti-extractable nuclear (ENA) Abs against sicca syndrome (SS)A 52 kDa, SSA 60 kDa, SSB, Smith (Sm), Sm-ribonucleoprotein (RNP), RNP A, and RNP 68 kDa antigens (Bioplex ® ); (iv) IgG anti-ribosomal Abs (Bioplex ® ); (v) IgG anti-C1q Abs (Quanta-lite ® , Werfen, Barcellona, Spain); and (vi) the spot urinary sCD163 (ELLA ® , Bio-techne, Minneapolis, MN) that was evaluated together with proteinuria and creatinuria (Cobas 500 ® ) in order to express sCD163 as a ratio to creatinuria, proteinuria, or not as well as the ratio of urine protein excretion to creatinine or PCR [ [22] , [23] , [24] , [25] , [26] ]. Cut-offs were fixed as recommended by the providers (C3 low <0.72 g/L; C4 low <0.11 g/L, CH50 low <31 %; anti-dsDNA Abs ≥10 international units [IU]/mL, anti-ENA/-Ribosomal/-Chromatin Abs ≥1.0 arbitrary units [AU]mL, and anti-C1q Abs ≥20 AU/mL) with the exception of the normalized urinary sCD163/creatinuria ratio as no consensus existed.…”
Section: Methodsmentioning
confidence: 99%
“…Data regarding disease activity using a cut-off point ≥5 from the SLEDAI-2K score [ 11 ], clinical presentation, current treatment, number and time of covid-19 vaccine injections or infectious episodes were retrospectively collected from medical records. Laboratory data included lymphocyte count, albumin and gamma-globulin levels using serum protein electrophoresis, IgG anti-double stranded (ds)DNA and anti-chromatin Abs (Bioplex, Biorad, Hercules, CA), IgG anti-extractable nuclear Abs, antiphospholipid Abs such as anticardiolipin (aCL) and anti-beta2 glycoprotein I (aβ2-GPI) Abs, and the complement fractions C3, C4 and CH50 (The Binding Site, Birmingham, UK) [ [12] , [13] , [14] , [15] ].…”
Section: Methodsmentioning
confidence: 99%
“…Interestingly, as presented by Garcia- Bravo, myositis-associated autoantibodies occurrence varied between the years 2020 and 2021, possibly due to both SARS-CoV-2 infection and vaccination. For instance, anti-MDA5 was the most common antibody detected in 2020, while anti-PL7 was most common during 2021 [ 157 , 158 ]. In the same regard, case reports of anti-MDA5 antibody dermatomyositis after allogeneic hematopoietic stem cell transplantation have been described [ 159 ].…”
Section: Autoimmune and Rheumatic Diseases During Auto13: (Diseases 1–9)mentioning
confidence: 99%